Investigational drug · Phase 2
ABBV-701
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "ABBV-701"
First trial start
2025
Apr 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-701", any sponsor or status.
Conditions studied
As listed on its trial records.
- Crohn's Disease
- Ulcerative Colitis
- Psoriatic Arthritis
Approved drugs for the same conditions: Psoriatic arthritis · Crohn's disease · Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-701" as an intervention, largest first.
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07697456 · 2,000 participants (planned) · Start Jul 31, 2026 · Primary completion Oct 2031
Drug: Risankizumab; Trosunilimab and 1 more · For: Crohn's Disease; Ulcerative Colitis
Sites: Dothan, Alabama; Phoenix, Arizona; Sun City, Arizona · 66 sites in all
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06865105 · 300 participants (planned) · Start Apr 11, 2025 · Primary completion Aug 2029
Drug: Lutikizumab; Risankizumab and 2 more · For: Psoriatic Arthritis
Sites: Huntington Beach, California; Avon Park, Florida; Clearwater, Florida · 41 sites in all
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian ParticipantsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06895343 · 100 participants · Start Apr 3, 2025 · Primary completion Nov 2026
Drug: ABBV-701; Placebo and 2 more · For: Healthy Volunteer
Sites: Anaheim, California; Grayslake, Illinois
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Crohn's Disease
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- JNJ-78934804JNJ-4804Phase 34 trials
Johnson & Johnson (Janssen) · Colitis, Ulcerative, Crohn's Disease, Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- AZD7798Phase 22 trials
AstraZeneca · Moderate to Severe Crohn's Disease, Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.